Fig. 1 · Structure

Documents & Downloads

Omecamtiv mecarbil (CK-1827452)

Cat. No. A11206 CAS 873697-71-3

Myosin activator

CK-1827452 is a selective cardiac specific myosin activator.

In Stock

Publications for Omecamtiv mecarbil

14 publications citing this product

  1. Isabella Leite Coscarella, .et al. , iScience, 2025, Oct 30;28(12):113901 PMID: 41321620
  2. Joohee Choi, .et al. , Am J Physiol Heart Circ Physiol, 2025, Jan 1;328(1):H161-H173 PMID: 39453428
  3. A. Balakin, .et al. , J Evol Biochem Physiol, 2023, 59: 1182-1194
  4. Oleg Lookin, .et al. , Clin Exp Pharmacol Physiol, 2021, Aug 29 PMID: 34459025
  5. Gabor A. Fulop, .et al. , Basic Res Cardiol, 2021, 116(1): 24 PMID: 33844095
  6. Wanjian Tang, .et al. , J Biol Chem, 2019, October 2 PMID: 31578282
  7. Thinh T. Kieu, .et al. , Biophysical Journal, 2019, 2019 PMID: 31103235
  8. Alexandre J. S. Ribeiro, .et al. , Circ Res, 2017, May 12; 120(10): 1572-1583 PMID: 28400398
  9. Anja M. Swenson, .et al. , J Biol Chem, 2017, Mar 3; 292(9): 3768-3778 PMID: 28082673
  10. Nánási P Jr, .et al. , Eur J Pharmacol, 2017, Aug 15;809:73-79 PMID: 28506910

Free Aliquoting for Your Order

Tell us your preferred amount per vial. We’ll confirm the options.

Biological Activity

Bioactivity / Mechanism

Omecamtiv mecarbil (CK-1827452) modulates cardiac myosin. In purified human β-cardiac myosin S1, it lowered maximal actin-activated ATPase turnover and reduced the actin concentration needed for half-maximal activity. In permeabilized failing human myocardium, it increased calcium sensitivity while slowing tension redevelopment; maximal isometric force was not significantly changed. These endpoints distinguish myosin modulation from a uniform increase in ATPase activity or force. [1]

Literature-reported observations and conditions; not Adooq-tested protocols or general treatment recommendations.

Target & Activity

Target Activity Value
Myosin ATPase

In Vitro Studies

Human myocardial responses depend on preparation and activation conditions. Nonfailing permeabilized single cardiomyocytes exposed to 1 µM omecamtiv mecarbil showed increased force at submaximal calcium but reduced maximal calcium-activated force, together with slower activation and relaxation and increased passive force. In failing multicellular myocardial preparations, 1 and 10 µM increased calcium sensitivity and slowed tension redevelopment without significantly changing maximal force. The reason for the different maximal-force responses remains undetermined. [2,1]

Actin-activated ATPase of human β-cardiac myosin S1

Biochemical assay · Purified recombinant human β-cardiac myosin subfragment 1 (M2β-S1); associated mouse light chains characterized in the original paper. [1]

OM reduced maximal actin-activated ATPase turnover and the actin concentration for half-maximal activity. The OM concentration-response endpoint was ATPase inhibition, despite the cardiac-myosin-activator designation.

Measured endpoints — not treatment concentrations
EndpointReported resultReference
Maximum actin-activated ATPase turnoverkcat 7.48 ± 1.07 s−1 (0.1% DMSO); 1.65 ± 0.05 s−1 (10 µM OM)[1]
Actin concentration for half-maximal ATPase activityKATPase 56.53 ± 13.92 µM (DMSO); 1.91 ± 0.44 µM (10 µM OM)[1]
Concentration-dependent inhibition of actin-activated ATPaseEC50 0.52 ± 0.10 µM[1]

Literature-Reported Treatment Conditions

Treatment concentration
10 µM OM for actin-dependence comparison; varying OM for concentration-response at 40 µM actin
Exposure duration
NADH absorbance monitored for 200 s
Method
NADH-linked ATPase assay; 100 nM M2β-S1, 0–60 µM actin, 1 mM MgATP in MOPS20 buffer (20 mM KCl)
Vehicle
0.1% DMSO comparison; buffer-only control also tested
Reported limits
ATPase assay temperature is not specified in the acquired Steady-state ATPase Activity subsection.
Methods and source locations

Compound reported in the paper: Omecamtiv mecarbil; Compound label in the paper: OM (CK-1827452)

Evidence concerns the named research compound in the reported preparation; no salt conversion or validation of the current Adooq lot.

Results: Actin-activated ATPase of M2β-S1; Fig. 2A-B; Table 1; Experimental Procedures: Reagents and Buffers, Steady-state ATPase Activity

Maximum actin-activated ATPase turnover: Hyperbolic fit versus actin concentration. Fig. 2 caption describes error bars as standard deviation of the mean from three protein preparations. — Table 1: 20 mM KCl + DMSO and 20 mM KCl + OM; Fig. 2A caption

Actin concentration for half-maximal ATPase activity: Michaelis-Menten actin-dependence fit; this is actin concentration, not OM potency. — Table 1: 20 mM KCl + DMSO and 20 mM KCl + OM

Concentration-dependent inhibition of actin-activated ATPase: OM concentration-response at 40 µM actin; fit to Equation 1. The result sentence does not separately define the ± term for this fitted EC50. — Results: Actin-activated ATPase of M2β-S1; Fig. 2B

Mechanics of permeabilized failing human myocardium

Cell-based study · 46 chemically permeabilized multicellular preparations from subendocardial left ventricular tissue of eight patients with end-stage heart failure; 15 °C, sarcomere length 2.24 µm. [1]

OM at 1 and 10 µM increased calcium sensitivity and slowed tension redevelopment. Maximum isometric force at pCa 4.5 was not significantly changed.

Measured endpoints — not treatment concentrations
EndpointReported resultReference
Maximal isometric force at pCa 4.5Effect versus vehicle No significant change[1]
Calcium sensitivity of forcepCa50 Increased significantly at 1 and 10 µM OM[1]
Rate of tension redevelopmentktr Decreased at 1 and 10 µM OM[1]

Literature-Reported Treatment Conditions

Treatment concentration
0 (control), 0.1, 1.0 or 10 µM OM; one concentration per preparation
Exposure duration
At least 3 min in relaxing solution containing the assigned OM concentration between trials
Method
Force-pCa curves and rapid shortening/re-stretch tension-recovery measurements; ionic strength 180 mM
Vehicle
0.67% DMSO in every experimental solution
Reported limits
No exact values inferred from the Fig. 8 bars.
Methods and source locations

Compound reported in the paper: Omecamtiv mecarbil; Compound label in the paper: OM (CK-1827452)

Evidence concerns the named research compound in the reported preparation; no salt conversion or validation of the current Adooq lot.

Results: Muscle Mechanics of Human Myocardium; Fig. 8; Experimental Procedures: Human Tissue through Statistics for Muscle Mechanics

Maximal isometric force at pCa 4.5: 46 preparations from eight hearts across all conditions; linear mixed model, Tukey-Kramer post hoc correction; total is not per-group n. — Results: Muscle Mechanics of Human Myocardium; Fig. 8A

Calcium sensitivity of force: Force-pCa relationship; image checked for direction, no bar-derived decimals. — Results: Muscle Mechanics of Human Myocardium; Fig. 8C image (caption panel labels reversed)

Rate of tension redevelopment: Rapid shortening/re-stretch and single-exponential recovery fit; image checked for direction. — Results: Muscle Mechanics of Human Myocardium; Fig. 8B image (caption panel labels reversed)

Force and calcium sensitivity in nonfailing human cardiomyocytes

Cell-based study · Permeabilized nonfailing human left ventricular cardiomyocytes at 15 °C and sarcomere length 2.3 µm. Supplement specifies four hearts for force measurements, 5–6 cells per heart; Fig. 1 specifies seven to nine determinations. [2]

OM increased calcium sensitivity and force at submaximal calcium, but reduced maximal calcium-activated force at 1 µM. Activation and relaxation slowed and passive force increased.

Measured endpoints — not treatment concentrations
EndpointReported resultReference
Calcium sensitivity of isometric forcepCa50 5.86 ± 0.02 (baseline) to 6.42 ± 0.06 (1 µM OM)[2]
Active force at submaximal calcium, pCa 6.2Factive 1.7 ± 0.3 to 8.6 ± 1.9 kN/m² with 1 µM OM[2]
Active force at maximal activation, pCa 4.75Factive 20.4 ± 2.0 to 11.0 ± 1.0 kN/m² with 1 µM OM[2]

Literature-Reported Treatment Conditions

Treatment concentration
0.1 and 1 µM OM for force-pCa curves; concentration-response measurements also shown in Fig. 1
Exposure duration
Incubation duration is not specified in the acquired human-cell force methods
Method
Isometric single-cell mechanics; comparisons with baseline without OM
Vehicle
DMSO stock solvent; final bath fraction not specified in the acquired force methods
Reported limits
Main Methods describes five donor hearts overall; supplement specifies four for force measurements. Exact per-condition allocation and incubation duration are not supplied in these passages.
Methods and source locations

Compound reported in the paper: Omecamtiv mecarbil; Compound label in the paper: OM

Evidence concerns the named research compound in the reported preparation; no salt conversion or validation of the current Adooq lot.

Methods: Human tissue source, Mechanical measurements, OM; Results first subsection; Fig. 1; Supplementary file2: Mechanical measurements on permeabilized myocytes, Statistics

Calcium sensitivity of isometric force: Mean ± SEM; Fig. 1 reports seven to nine individual measurements. — Results first subsection; Fig. 1C-D

Active force at submaximal calcium, pCa 6.2: Isometric force normalized to cell cross-sectional area; mean ± SEM. — Results first subsection; Fig. 1E

Active force at maximal activation, pCa 4.75: Isometric force normalized to cell cross-sectional area; mean ± SEM. — Results first subsection; Fig. 1E

In Vivo Studies

In healthy rats, acute intravenous omecamtiv mecarbil escalation increased echocardiographic ejection fraction and systolic ejection time while impairing diastolic indices. A separate arterial-pressure experiment found severe hypotension at the highest cumulative dose, 1200 µg/kg, without a significant heart-rate change. These acute findings in healthy animals do not establish a chronic therapeutic window; the authors also identify anesthesia as a possible contributor to hypotension. [2]

Systolic and diastolic echocardiography during acute OM escalation

Animal study · Healthy male Wistar–Kyoto rats, 13–15 weeks; ketamine/xylazine anesthesia (50/5 mg/kg). [2]

Cumulative OM increased ejection fraction and systolic ejection time, while prolonging isovolumetric relaxation and increasing left atrial area. Better systolic indices therefore coincided with impaired diastolic function.

Conditions shared by the study groups

Route
Intravenous, left jugular vein
Frequency
Three consecutive boluses during acute assessment
Treatment course
Complete ultrasound assessment after each dose
Vehicle
DMSO; solvent tested before OM
Study groups and reported outcomes
Group / doseComparatorObserved resultReference
OM cumulative intravenous escalation
200, then 400, then 600 µg/kg incremental boluses; cumulative 200, 600 and 1200 µg/kg
Initial baseline and preceding solvent assessmentAt cumulative 1200 µg/kg: ejection fraction 73.3 ± 2.2 to 87.4 ± 3.6%; systolic ejection time 75.2 ± 2.5 to 117.4 ± 6.1 ms; isovolumetric relaxation time 25.6 ± 1.6 to 52.7 ± 2.7 ms; left atrial area 29.4 ± 1.7 to 48.3 ± 2.0 mm². Mean ± SEM; n=8–14 for systolic and n=7–14 for diastolic echocardiographic observations, varying by endpoint.[2]
OM cumulative intravenous escalation
Model: Healthy male Wistar–Kyoto rats, 13–15 weeks; ketamine/xylazine anesthesia (50/5 mg/kg).
Reported limits: The echocardiographic methods do not state an exact interval between boluses; the 12–15 min interval in the pressure-volume methods is not borrowed here. Final injected DMSO fraction not specified.
Methods and source locations

Compound reported in the paper: Omecamtiv mecarbil; Compound label in the paper: OM

Evidence concerns the named research compound in the reported preparation; no salt conversion or validation of the current Adooq lot.

Methods: Animal experiments, Echocardiography, OM; Results positive inotropy and diastolic dysfunction; Fig. 2A, Fig. 3A; Supplementary file2: Echocardiography, Statistics

OM cumulative intravenous escalation · Methods: Animal experiments, Echocardiography, OM; Results positive inotropy and diastolic dysfunction; Fig. 2A, Fig. 3A; Supplementary file2: Echocardiography, Statistics

Arterial pressure during acute OM escalation

Animal study · Healthy male Wistar–Kyoto rats, 13–15 weeks; invasive carotid blood pressure and simultaneous ECG recording. [2]

The highest cumulative OM dose caused severe hypotension without a significant change in heart rate. DMSO alone caused a transient pressure fall that recovered within 5 min.

Conditions shared by the study groups

Route
Intravenous, left jugular vein
Frequency
Three consecutive boluses during acute assessment
Treatment course
Immediate pre-bolus and 5-min post-bolus assessments
Vehicle
DMSO solvent assessment precedes OM
Study groups and reported outcomes
Group / doseComparatorObserved resultReference
OM escalation with arterial monitoring
200, then 400, then 600 µg/kg incremental boluses; cumulative 200, 600 and 1200 µg/kg
Pre-bolus baseline and DMSO-alone recordingAt cumulative 1200 µg/kg: systolic pressure 149 ± 6 to 49 ± 6 mmHg and diastolic pressure 130 ± 4 to 37 ± 7 mmHg (each P<0.05). Heart rate 443 ± 18 to 445 ± 16 beats/min, without a significant effect. Mean ± SEM; six replicates in Fig. 4.[2]
OM escalation with arterial monitoring
Model: Healthy male Wistar–Kyoto rats, 13–15 weeks; invasive carotid blood pressure and simultaneous ECG recording.
Reported limits: Final injected DMSO fraction not specified. The separate blood-pressure subsection does not explicitly identify its anesthetic regimen; do not borrow the echo or pressure-volume regimen.
Methods and source locations

Compound reported in the paper: Omecamtiv mecarbil; Compound label in the paper: OM

Evidence concerns the named research compound in the reported preparation; no salt conversion or validation of the current Adooq lot.

Methods: Invasive blood pressure measurement, OM; Results: hypotension; Fig. 4; Supplementary file2: Blood pressure measurement, Statistics

OM escalation with arterial monitoring · Methods: Invasive blood pressure measurement, OM; Results: hypotension; Fig. 4; Supplementary file2: Blood pressure measurement, Statistics

Specifications

Manufacturer Adooq Bioscience
Actions Activator
CAS Number 873697-71-3
Applications Myosin activator
Formula C20H24FN5O3
Molecular Weight 401.43
Synonyms CK1827452
SMILES
CC1=NC=C(C=C1)NC(=O)NC2=CC=CC(=C2F)CN3CCN(CC3)C(=O)OC

Storage & Solubility

In Vitro Solubility

Reported Solubility

SolventReported Solubility
DMSO 73 mg/mL (181.84 mM)
Water Insoluble
Ethanol 5 mg/mL (12.45 mM)

Preparing Stock Solutions

Stock preparation is unavailable for this product molecular weight.

Calculated stock concentrations do not establish solvent solubility. Refer to the reported solubility data for experimental guidance.

In Vivo Preparation

Concentration
28 mg/mL
Vehicle
1% DMSO+30% polyethylene glycol+1% Tween 80

Storage

Store powder at -20°C, keep desiccated.
In powder form, the chemical is stable for 36 months.
In solution, store at -20°C and use within 1 month to prevent loss of potency. Aliquot to avoid multiple freeze/thaw cycles.

Research References

  1. [1] Swenson AM, Tang W, Blair CA, et al. Omecamtiv Mecarbil Enhances the Duty Ratio of Human β-Cardiac Myosin Resulting in Increased Calcium Sensitivity and Slowed Force Development in Cardiac Muscle J Biol Chem (2017). PMID: 28082673 DOI: 10.1074/jbc.m116.748780 Source material
  2. [2] Fülöp GÁ, Oláh A, Csipo T, et al. Omecamtiv mecarbil evokes diastolic dysfunction and leads to periodic electromechanical alternans Basic Res Cardiol (2021). PMID: 33844095 DOI: 10.1007/s00395-021-00866-8 Source material

Publications

14 publications citing this product

  1. Isabella Leite Coscarella, .et al. , iScience, 2025, Oct 30;28(12):113901 PMID: 41321620
  2. Joohee Choi, .et al. , Am J Physiol Heart Circ Physiol, 2025, Jan 1;328(1):H161-H173 PMID: 39453428
  3. A. Balakin, .et al. , J Evol Biochem Physiol, 2023, 59: 1182-1194
  4. Oleg Lookin, .et al. , Clin Exp Pharmacol Physiol, 2021, Aug 29 PMID: 34459025
  5. Gabor A. Fulop, .et al. , Basic Res Cardiol, 2021, 116(1): 24 PMID: 33844095
  6. Wanjian Tang, .et al. , J Biol Chem, 2019, October 2 PMID: 31578282
  7. Thinh T. Kieu, .et al. , Biophysical Journal, 2019, 2019 PMID: 31103235
  8. Alexandre J. S. Ribeiro, .et al. , Circ Res, 2017, May 12; 120(10): 1572-1583 PMID: 28400398
  9. Anja M. Swenson, .et al. , J Biol Chem, 2017, Mar 3; 292(9): 3768-3778 PMID: 28082673
  10. Nánási P Jr, .et al. , Eur J Pharmacol, 2017, Aug 15;809:73-79 PMID: 28506910
  11. Horváth B, .et al. , Naunyn Schmiedebergs Arch Pharmacol, 2017, Dec;390(12):1239-1246 PMID: 28940010
  12. Szentandrassy N, .et al. , J Physiol Pharmacol, 2016, Aug;67(4):483-489 PMID: 27779469
  13. L Nagy, .et al. , Br J Pharmacol, 2015, Sep; 172(18): 4506-4518 PMID: 26140433
  14. Larissa Butler, .et al. , Toxicol Sci, 2015, Jun;145(2):396-406 PMID: 25820236

Showing 10 of 14 publications

Added to your cart

View Cart Checkout
Loading...